Regulatory approval

Published by the Health Service Executive. Withdrawn

The Republic of Ireland's Health Service Executive (HSE) has approved gemcitabine in combination with carboplatin (AUC2) - 21 days for reimbursement as a treatment option for the treatment of locally recurrent metastatic triple negative breast cancer.

This is written in the approval document as:

Treatment of locally recurrent metastatic triple negative breast cancer.

Reimbursement

N/A

Citation

Gemcitabine and CARBOplatin (AUC2) Therapy - 21 days, 2026, version number 6, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6832/430_v5_GemcarboAUC2_csa5PxW.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2017-06-14	Health Service Executive	Indication approved for reimbursement.